BiolineRx
BioLineRx is a Jerusalem-based clinical-stage biopharmaceutical company developing oncology and rare disease therapies, with FDA-approved APHEXDA (motixafortide) for multiple myeloma stem cell mobilization and pipeline assets GLIX1 for glioblastoma and motixafortide in pancreatic cancer.
- Company typePublic
- Founded2003
- HeadquartersJerusalem, Israel
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What BiolineRx does
BioLineRx Ltd. is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, listed on NASDAQ (BLRX) and TASE. The company focuses on developing therapeutics for oncology and rare diseases, anchored by two technology platforms: CXCR4 inhibition via motixafortide and TET2 pathway activation via GLIX1. Its commercial asset, APHEXDA (motixafortide), is an FDA-approved subcutaneous CXCR4 antagonist for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation.
The company's pipeline includes motixafortide in Phase 2b development for first-line metastatic pancreatic cancer (CheMo4METPANC trial co-supported with Regeneron and Columbia University) and Phase 1 evaluation for sickle cell disease stem cell mobilization with St. Jude and Washington University. GLIX1, a first-in-class oral small molecule restoring TET2 activity to selectively kill cancer cells, entered Phase 1/2a trials in glioblastoma in March 2026 under a joint venture with Hemispherian AS. USPTO patent protection on GLIX1 extends through 2040 across cancer types where cytidine deaminase is not over-expressed (over 90% of cancers).
BioLineRx operates an asset-light, partner-driven commercial model. APHEXDA is commercialized globally ex-Asia through an exclusive license to Ayrmid Ltd. (parent of Gamida Cell) and in Asia through Gloria Biosciences, generating royalty revenue of $480,000 in Q1 2026 (up 88% YoY). FY2025 revenue was $1.2M with a net loss of $2M. The company held $17.4M in cash as of Q1 2026, providing runway into H1 2027. Trial execution and pipeline progression are largely outsourced to academic medical centers (Columbia, NYU Langone, Northwestern, Moffitt, Washington University, St. Jude), with a lean internal team of 51-100 employees concentrated in clinical operations, regulatory affairs, and chemistry.
BiolineRx firmographics
Firmographics- Name
- BiolineRx
- Legal name
- BioLineRx Ltd.
- Website
- https://biolinerx.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BioLineRx is a Jerusalem-based clinical-stage biopharmaceutical company developing oncology and rare disease therapies, with FDA-approved APHEXDA (motixafortide) for multiple myeloma stem cell mobilization and pipeline assets GLIX1 for glioblastoma and motixafortide in pancreatic cancer.
- Ownership category
- akta.pro rank
BiolineRx industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)
Keywords
Where BiolineRx is headquartered
LocationHeadquarters
- HQ city
- Jerusalem
- HQ country
- Israel
- HQ region
- Middle East
Markets served
BiolineRx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- APHEXDA Product Sales: Revenue generated from commercialization of APHEXDA (motixafortide) for stem cell mobilization in multiple myeloma patients through licensing partner Ayrmid Ltd.
- Royalties from APHEXDA: Q1 2026 revenue of $480,000, up 88% year-over-year, driven by increased royalties from APHEXDA commercialization with Ayrmid Ltd. and Gloria Biosciences.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
BiolineRx product offering
Product offeringCore offering
BioLineRx develops and out-licenses novel biopharmaceutical therapies for oncology and rare diseases. Its commercial product APHEXDA (motixafortide) is a CXCR4 antagonist approved by the FDA for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. The pipeline extends motixafortide into metastatic pancreatic cancer and sickle cell disease, and adds GLIX1, a first-in-class oral TET2 activator in Phase 1/2a for glioblastoma and other solid tumors. Revenue is generated through licensing royalties from commercialization partners Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia).
Product overview
BiolineRx is a clinical-stage biopharmaceutical company advancing an innovative pipeline of therapeutics for patients with cancer and rare diseases. The company's portfolio includes APHEXDA (motixafortide), an FDA-approved stem cell mobilization agent commercialized by partner Ayrmid Ltd., as well as motixafortide which is further being developed for pancreatic cancer (Phase 2) and sickle cell disease (Phase 1). The lead development asset is GLIX1, a first-in-class oral small molecule targeting DNA damage response via TET2 restoration, currently in Phase 1/2a clinical trials for glioblastoma. BiolineRx leverages full-spectrum drug development capabilities including chemistry, analytics, nonclinical and clinical development, and commercialization expertise.
Differentiator
Problem solved
Functional benefit
Brands
- APHEXDA: FDA-approved stem cell mobilization product (motixafortide) for multiple myeloma patients
Products and services
- APHEXDA (motixafortide) APHEXDA (motixafortide) is an FDA-approved CXCR4 antagonist administered as a subcutaneous injection for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. It is BioLineRx's only commercially approved product, generating royalty revenue through the licensing partner Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia). The same molecule (motixafortide) is also being developed in pipeline indications including metastatic pancreatic cancer (Phase 2b CheMo4METPANC trial) and sickle cell disease stem cell mobilization for gene therapy (Phase 1, in collaboration with Washington University and St. Jude).
- GLIX1 GLIX1 is a first-in-class oral small molecule that targets DNA damage repair by restoring TET2 activity, promoting selective cancer-cell killing while sparing normal cells. It is brain-penetrant and in Phase 1/2a clinical development for glioblastoma and other high-grade gliomas, with potential applications across approximately 90% of cancer types where cytidine deaminase is not over-expressed. The asset is being advanced through the BioLineRx-Hemispherian joint venture established in Q3 2025.
Quantifiable outcome
- 6.5 months median overall survival vs 4.7 months historical data in metastatic pancreatic cancer (COMBAT study)
- +5 more outcomes
Companies that use BiolineRx
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles2 records
BiolineRx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BiolineRx partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Hemispherian AScoreCollaboration agreement to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response by restoring TET2 activity. A joint venture was established in Q3 2025 to advance GLIX1 clinical development for glioblastoma and other cancers. First-in-human Phase 1/2a trial initiated March 2026 at NYU Langone Health, Northwestern University, and Moffitt Cancer Center.
- Ayrmid Ltd. (Gamida Cell Ltd.)coreLicense agreement granting Ayrmid exclusive rights to develop and commercialize APHEXDA (motixafortide) across all indications except solid tumor indications, in all territories other than Asia. Ayrmid leads US commercialization of the approved stem cell mobilization product and the St. Jude sickle cell disease program.
- St. Jude Children's Research HospitalminorClinical trial collaboration for multi-center Phase 1 clinical trial evaluating safety, tolerability, and feasibility of single-agent motixafortide for mobilization and collection of CD34+ hematopoietic stem cells in 12 patients aged 18+ with sickle cell disease. Through APHEXDA development agreement with Ayrmid, Gamida Cell leads this program.
- Gloria BiosciencescoreAgreement for development and commercialization of motixafortide across all indications in Asia. GloriaBio plans to lead a bridging study to support potential approval and commercialization of motixafortide in stem cell mobilization for autologous transplantation in patients with multiple myeloma in China, and a randomized Phase 2 trial in first-line pancreatic cancer with zimberelimab and chemotherapy.
- Columbia UniversitycoreSponsor of CheMo4METPANC randomized Phase 2b clinical trial evaluating motixafortide in combination with PD-1 inhibitor cemiplimab (LIBTAYO) and standard chemotherapy vs chemotherapy alone in 108 first-line metastatic pancreatic cancer patients. Trial equally supported by BioLineRx and Regeneron.
- RegeneronminorCo-supporter of the CheMo4METPANC randomized Phase 2b clinical trial in first-line metastatic pancreatic cancer, equally sharing development costs with BioLineRx.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
BiolineRx competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BiolineRx social profiles
Digital presenceBiolineRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
BiolineRx leadership team
Management profileNumber of profiles
Profiles19 records
BiolineRx subsidiaries and ownership
Company hierarchySubsidiaries1 record
BiolineRx funding detail
Funding detailFunding overview
Funding rounds19 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BiolineRx M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BiolineRx
What does BiolineRx do?
BioLineRx develops and out-licenses novel biopharmaceutical therapies for oncology and rare diseases. Its commercial product APHEXDA (motixafortide) is a CXCR4 antagonist approved by the FDA for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. The pipeline extends motixafortide into metastatic pancreatic cancer and sickle cell disease, and adds GLIX1, a first-in-class oral TET2 activator in Phase 1/2a for glioblastoma and other solid tumors. Revenue is generated through licensing royalties from commercialization partners Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia).
Is BiolineRx a public or private company?
BiolineRx is a public company. It is classified as public and is currently operating.
When was BiolineRx founded?
BiolineRx was founded in 2003. It employs 51 to 100 people.
Where is BiolineRx based?
BiolineRx is headquartered in Jerusalem, Israel, in the Middle East region.
How does BiolineRx make money?
Two revenue lines are on record. APHEXDA Product Sales are the primary driver. The others are royalties from APHEXDA.
Does BiolineRx have an API?
No public API is recorded for BiolineRx.
What industry is BiolineRx in?
BiolineRx's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325412 and its SIC code is 2834.